全文获取类型
收费全文 | 1133篇 |
免费 | 85篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 32篇 |
妇产科学 | 61篇 |
基础医学 | 91篇 |
口腔科学 | 9篇 |
临床医学 | 49篇 |
内科学 | 194篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
特种医学 | 69篇 |
外科学 | 630篇 |
综合类 | 26篇 |
预防医学 | 8篇 |
眼科学 | 2篇 |
药学 | 18篇 |
中国医学 | 3篇 |
肿瘤学 | 15篇 |
出版年
2016年 | 6篇 |
2015年 | 6篇 |
2013年 | 10篇 |
2012年 | 6篇 |
2010年 | 5篇 |
2009年 | 5篇 |
2008年 | 10篇 |
2007年 | 15篇 |
2006年 | 13篇 |
2005年 | 12篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 13篇 |
2001年 | 21篇 |
2000年 | 31篇 |
1999年 | 46篇 |
1998年 | 23篇 |
1997年 | 22篇 |
1996年 | 20篇 |
1995年 | 27篇 |
1994年 | 21篇 |
1993年 | 33篇 |
1992年 | 71篇 |
1991年 | 119篇 |
1990年 | 92篇 |
1989年 | 77篇 |
1988年 | 60篇 |
1987年 | 48篇 |
1986年 | 36篇 |
1985年 | 39篇 |
1984年 | 21篇 |
1983年 | 22篇 |
1982年 | 7篇 |
1980年 | 11篇 |
1979年 | 17篇 |
1978年 | 13篇 |
1977年 | 17篇 |
1976年 | 6篇 |
1975年 | 12篇 |
1974年 | 9篇 |
1973年 | 14篇 |
1972年 | 17篇 |
1971年 | 21篇 |
1970年 | 24篇 |
1969年 | 12篇 |
1968年 | 17篇 |
1967年 | 11篇 |
1966年 | 11篇 |
1957年 | 6篇 |
1954年 | 5篇 |
排序方式: 共有1219条查询结果,搜索用时 15 毫秒
81.
82.
83.
84.
85.
86.
B S Husberg K Bakshandeh J Lilly R Pfister D P Stables T E Starzl 《Acta chirurgica Scandinavica》1975,141(6):557-563
Five cases of renal autotransplantation representing five different indications for the procedure are presented and discussed. 相似文献
87.
McCurry KR Iacono A Zeevi A Yousem S Girnita A Husain S Zaldonis D Johnson B Hattler BG Starzl TE 《The Journal of thoracic and cardiovascular surgery》2005,130(2):528-537
OBJECTIVES: Acute and chronic rejection remain unresolved problems after lung transplantation, despite heavy multidrug immunosuppression. In turn, the strong immunosuppression has been responsible for mortality and pervasive morbidity. It also has been postulated to interdict potential mechanisms of alloengraftment. METHODS: In 48 lung recipients we applied 2 therapeutic principles: (1) recipient pretreatment with antilymphoid antibody preparations (Thymoglobulin [SangStat, Fremont, Calif] or Campath [alemtuzumab; manufactured by ILEX Pharmaceuticals, LP, San Antonio, Tex; distributed by Berlex Laboratories, Richmond, Calif]) and (2) minimal posttransplant immunosuppression with tacrolimus monotherapy or near-monotherapy. Our principal analysis was of the events during the critical first 6 posttransplant months of highest immunologic and infectious disease risk. Results were compared with those of 28 historical lung recipients treated with daclizumab induction and triple immunosuppression (tacrolimus-prednisone-azathioprine). RESULTS: Recipient pretreatment with both antilymphoid preparations allowed the use of postoperative tacrolimus monotherapy with prevention or control of acute rejection. Freedom from rejection was significantly greater with Campath than with Thymoglobulin (P = .03) or daclizumab (P = .05). After lymphoid depletion with Thymoglobulin or Campath, patient and graft survival at 6 months was 90% or greater. Patient and graft survival after 9 to 24 months is 84.2% in the Thymoglobulin cohort, and after 10 to 12 months, it is 90% in the Campath cohort. There has been a subjective improvement in quality of life relative to our historical experience. CONCLUSION: Our results suggest that improvements in lung transplantation can be accomplished by altering the timing, dosage, and approach to immunosuppression in ways that might allow natural mechanisms of alloengraftment and diminish the magnitude of required maintenance immunosuppression. 相似文献
88.
89.